Stellarex Drug-Coated Balloon Animation


The Stellarex drug-coated balloon (DCB) is an angioplasty balloon with EnduraCoat technology allowing the treatment of arterial lesions in peripheral artery disease (PAD) with a low drug dose. We developed an animation for Philips showing the mechanism of action (MoA) of their Stellarex DCB platform. The animation follows the therapy device as it is guided along the artery before arriving at the lesion site. It then looks at how the combined effects of the angioplasty balloon and low drug dose target the lesion and allow normal blood flow to resume.

The animation is housed on the Philip’s Stellarex product page showcasing it as an innovative image-guided therapy device.

Are you interested in seeing how our award-winning medical animation can help you?

Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.


GSK Random42 client

‘‘For experts, there’s limited time in which they will interact with this content, so getting a message across quickly is crucial, and this medium does it very well.
Product Manager, GSK

BMS logo Random42 client

‘‘Their turnaround time sets them apart from the rest of the field. The fact they can turnaround lots of comments in a couple of days is impressive, whereas that took weeks with other agencies we worked with. They’re well above the benchmark.
Oncology Clinical Liaison, Bristol-Myers Squibb

‘‘It was a combination equally of quality of work but also the comfort and confidence that I knew I would be working with PhDs. They gave me the confidence that they would have the ability to understand. The other companies didn’t have those sorts of people on staff, they were just good animators. That was the area where I felt that I could trust Random42 would deliver.’’
Senior Product Manager, Spectranetics

Amgen Logo

‘‘I have been to a lot of conferences and I have seen a lot of videos both from competitors and internally – in my eyes it is night and day. The quality Random42 have is not one step ahead, it is far ahead compared to what I have seen before.’’
Product Manager, Amgen